On the public citation graph
A Phase II Study of Durvalumab and Tremelimumab in Patients with Advanced Rare Cancer
0 signed · 35 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/jso.24266openalex-extracted
Programmed death ligand‐1 expression is associated with poor disease free survival in salivary gland carcinomas
inferredcites →https://doi.org/10.1016/j.annonc.2021.11.009openalex-extracted
Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary
inferredcites →https://doi.org/10.1016/j.ejca.2018.02.021openalex-extracted
Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy
inferredcites →https://doi.org/10.1016/j.ygyno.2018.09.001openalex-extracted
Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management
inferredcites →https://doi.org/10.1016/s1470-2045(10)70245-xopenalex-extracted
Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review
inferredcites →https://doi.org/10.1016/s1470-2045(17)30104-3openalex-extracted
Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study
inferredcites →https://doi.org/10.1016/s1470-2045(17)30624-1openalex-extracted
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
inferredcites →https://doi.org/10.1016/s1470-2045(18)30006-8openalex-extracted
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials
inferredcites →https://doi.org/10.1016/s2468-1253(21)00382-4openalex-extracted
Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study
inferredcites →https://doi.org/10.1038/nrc3239openalex-extracted
The blockade of immune checkpoints in cancer immunotherapy
inferredcites →https://doi.org/10.1038/nrc3838openalex-extracted
Translational biology of osteosarcoma
inferredcites →https://doi.org/10.1038/s41591-023-02518-xopenalex-extracted
Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial
inferredcites →https://doi.org/10.1038/s41598-019-49215-9openalex-extracted
The expression of PD-L1 in salivary gland carcinomas
inferredcites →https://doi.org/10.1056/nejmoa1504030openalex-extracted
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
inferredcites →https://doi.org/10.1056/nejmoa1709030openalex-extracted
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
inferredcites →https://doi.org/10.1056/nejmoa1802357openalex-extracted
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
inferredcites →https://doi.org/10.1056/nejmoa1910231openalex-extracted
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1080/2162402x.2016.1277308openalex-extracted
Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression
inferredcites →https://doi.org/10.1097/coc.0000000000000429openalex-extracted
Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma
inferredcites →https://doi.org/10.1111/j.1600-065x.2008.00662.xopenalex-extracted
Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways
inferredcites →https://doi.org/10.1111/nyas.12180openalex-extracted
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
inferredcites →https://doi.org/10.1136/jitc-2022-004822openalex-extracted
Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial
inferredcites →https://doi.org/10.1155/2014/391967openalex-extracted
Sarcoma Immunotherapy: Past Approaches and Future Directions
inferredcites →https://doi.org/10.1158/1078-0432.ccr-15-0831openalex-extracted
New Strategies in Sarcoma: Linking Genomic and Immunotherapy Approaches to Molecular Subtype
inferredcites →https://doi.org/10.1158/1940-6207.capr-15-0316openalex-extracted
Whole-Genome Sequencing of Salivary Gland Adenoid Cystic Carcinoma
inferredcites →https://doi.org/10.1200/edbk_158712openalex-extracted
Immunotherapy: Beyond Anti–PD-1 and Anti–PD-L1 Therapies
inferredcites →https://doi.org/10.1200/jco.20.6.1651openalex-extracted
Gemcitabine, Carboplatin, and Paclitaxel for Patients With Carcinoma of Unknown Primary Site: A Minnie Pearl Cancer Research Network Study
inferredcites →https://doi.org/10.1200/jco.2015.62.3397openalex-extracted
Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
inferredcites →https://doi.org/10.1200/jco.2022.40.16_suppl.5598openalex-extracted
Stage 1 results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas (NCT03355976).
inferredcites →https://doi.org/10.1200/jco.2023.41.16_suppl.6092openalex-extracted
A phase II trial of nivolumab for patients with platinum-refractory recurrent or metastatic salivary gland cancer.
inferredcites →https://doi.org/10.1634/theoncologist.2014-0468openalex-extracted
Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review
inferredcites →https://doi.org/10.2217/fon.15.329openalex-extracted
Unknown Primary Tumors: Is there a Future Therapeutic Role for Immune Checkpoint Inhibitors?
inferredcites →https://doi.org/10.2217/imt.13.9openalex-extracted
Tremelimumab: A Review of Development to Date in Solid Tumors
inferredcites →https://doi.org/10.3390/cancers12092516openalex-extracted
Evaluation of PD-L1 Expression and HPV Genotyping in Anal Squamous Cell Carcinoma
inferredcites →https://doi.org/10.3802/jgo.2017.28.e20openalex-extracted
Update on immune checkpoint inhibitors in gynecological cancers
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.